Genus PLC
LSE:GNS
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Genus PLC
Total Receivables
Genus PLC
Total Receivables Peer Comparison
Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Genus PLC
LSE:GNS
|
Total Receivables
ÂŁ126.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
5%
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Total Receivables
$39.1m
|
CAGR 3-Years
138%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Exscientia PLC
NASDAQ:EXAI
|
Total Receivables
ÂŁ35.9m
|
CAGR 3-Years
77%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Total Receivables
$24.5m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Total Receivables
$39.1m
|
CAGR 3-Years
42%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Total Receivables
ÂŁ61.4m
|
CAGR 3-Years
54%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
See Also
What is Genus PLC's Total Receivables?
Total Receivables
126.1m
GBP
Based on the financial report for Dec 31, 2023, Genus PLC's Total Receivables amounts to 126.1m GBP.
What is Genus PLC's Total Receivables growth rate?
Total Receivables CAGR 10Y
5%
Over the last year, the Total Receivables growth was 0%. The average annual Total Receivables growth rates for Genus PLC have been 6% over the past three years , 6% over the past five years , and 5% over the past ten years .